Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
Investing.com - Barclays (LON:BARC) maintained its Equalweight rating on Insulet Corporation (NASDAQ:PODD) while raising its price target to $300 from $266 on Thursday. The medical device maker has shown impressive momentum, with the stock trading near its 52-week high of $333.41 and delivering a remarkable 79% return over the past year.
The research firm cited stronger sales projections as the primary reason for the increased target, adjusting its sales forecast upward by approximately 6% for 2025, aligning with management’s updated outlook. According to InvestingPro data, the company has demonstrated robust revenue growth of 26% in the last twelve months, supported by a healthy gross margin of 70%.
Barclays has also increased its sales projections by 7-8% on average per year for 2026 and beyond, while raising its earnings per share estimate by approximately 12% for 2025 and by roughly 21% on average annually for 2026 and beyond.
The new $300 price target is based on a 6.5x EV/Sales multiple applied to Barclays’ projected next-twelve-months sales of $3.3 billion, up from the previous projection of $2.9 billion.
Barclays noted that its target multiple represents a discount to both Insulet’s current multiple of approximately 8.0x and its long-term average of 11-12x.
In other recent news, Insulet Corporation delivered strong second-quarter results for 2025, surpassing both earnings and revenue forecasts. The company reported earnings per share of $1.17, significantly above the projected $0.92, and revenue of $649 million, exceeding expectations of $614.18 million. This represented a 31% year-over-year growth in revenue. Following these results, several analyst firms adjusted their price targets for Insulet. RBC Capital raised its price target to $350 from $330, citing the company’s robust quarterly performance. Similarly, Canaccord Genuity increased its target to $353 from $331, highlighting Insulet’s strong growth across all markets. Jefferies also revised its target upward to $375 from $360 after the company reported 31% growth excluding foreign exchange effects. Additionally, Bernstein SocGen Group raised its price target to $400 from $375, noting Insulet’s consistent growth and the expected continuation of over 20% growth for the tenth consecutive year by 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.